Secondly, systemic therapy approaches have evolved over this extensive study period, for instance, the large-scale use of targeted drugs for HER-2 positive breast cancer and neoadjuvant immunotherapy for triple-negative breast cancer (46). Here, ERBB2 is linked to triple-negative breast carcinoma.